UNSPSC 51151552: Ipidacrine

This classification denotes an anticholinergic agent with the molecular structure C12H16N2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, CV71VTP0VN chemically known as 9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinoline, but more commonly known as ipidacrine, which bears U.S. NIH Compound Identifier 604519. European Medicines Agency schedules Ipidacrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08273MIG.

The term IPIDACRINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 10, no. 3, 1996, list 36).

UNSPSC 51151552 Ipidacrine is a Commodity code covering pharmaceutical products and related drug-delivery systems procured by state and local health agencies. Recent state and local opportunities under this code reflect purchases of naloxone (opioid reversal medication) and safe drug deactivation systems, alongside exploratory procurement for direct-to-manufacturer prescription fulfillment programs. State and local issuing bodies soliciting under this code include county health departments and state health and human services commissions; Seminole County, Florida and the Texas Health and Human Services Commission appear as active buyers in the current market. The work being solicited ranges from routine annual procurement of naloxone and deactivation equipment to more complex strategic initiatives redesigning pharmacy benefit delivery channels outside traditional pharmacy benefit manager and group purchasing organization arrangements.

Recent activity shows geographic concentration in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford; the IFB required bids by July 26, 2023, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as a market-intelligence vehicle to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; the RFI sought information on vendors' capacity for direct contracting outside existing PBM and GPO arrangements, value-based pricing models, and multi-jurisdictional government health plan participation, with no formal award value or timeline specified at the information-gathering phase.